Eculizumab allows plasma exchnage discontinuation after a third kidney transplantation in a patient with plasma dependent atypical hus due to CFH mutation

Authors
Publication date
1 September 2009
Publisher
Springer no. M136

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Newcastle University E-Prints

    redirect
    oaioai:eprints.ncl.ac.uk:148642
    Last time updated on 30/05/2021